

RECEIVED
CENTRAL FAX CENTER

JAN 16 2007



FACSIMILE COVER SHEET

January 16, 2007

Receiver: Central Fax Number/Examiner Herbert J. Lilling
USPTO

TEL #:

FAX #: 571-273-8300

Sender: Mary Terry, Patent Secretary for Jeffrey K. Weaver

Our Ref. No.: CYTOP135

Your Ref: 10/623,486

Re: Amendment B

Pages Including Cover Sheet(s): 7

FAX CONTENTS:

Fax Cover Sheet -- 1 page

Amendment B -- 5 Page

Amendment Transmittal -- 1 pages

MESSAGE:

CONFIDENTIALITY NOTE

The information contained in this facsimile (FAX) message is legally privileged and confidential information intended only for the use of the receiver or firm named above. If the reader of this message is not the intended receiver, you are hereby notified that any dissemination, distribution or copying of this FAX is strictly prohibited. If you have received this FAX in error, please immediately notify the sender at the telephone number provided below and return the original message to the sender at the address below via the United States Postal Service. Thank you.

Beyer Weaver LLP • 500 12th Street, Suite 200, Oakland, CA 94607 • Phone 510.663.1150 • Fax 510.663.0920 • www.beycrllaw.com

San Francisco • Minneapolis • Oakland

JAN 16 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mattheakis et al.

Attorney Docket No.: CYTOP135

Application No.: 10/623,486

Examiner: LILLING, HERBERT J


Filed: July 18, 2003

Group: 1651

Title: PREDICTING HEPATOTOXICITY
USING CELL BASED ASSAYS**CERTIFICATE OF FACSIMILE TRANSMISSION:**

I hereby certify that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, Attn: Examiner Kailash, Fax No. (571) 273-8300, Alexandria, VA 22313-1450 on: January 16, 2007.

Signed:


 Mary Terry
AMENDMENT TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BEST AVAILABLE COPY

Sir:


Transmitted herewith is an Amendment in the above-identified application.

The fee has been calculated as shown below.

	Claims After Amendment		Highest Previously Paid For	Present Extra	Small Entity Rate Fee	Large Entity Rate Fee
Total Claims	19	MINUS	19	0	x 25 =	x 50 = 0
Independent Claims	3	MINUS	3	0	x 100 =	x 200 = 0
Multiple Dependent Claim Present and Fee Not Previously Paid						
Total					\$	\$0

- ☒ Applicant(s) hereby petition for a 1 month extension(s) of time to respond to the aforementioned Office Action.
- ☒ Applicant(s) believe that no (additional) Extension of Time is required; however, if it is determined that such an extension is required, Applicant(s) hereby petition that such an extension be granted and authorize the Commissioner to charge the required fees for an Extension of Time under 37 CFR 1.136 to Deposit Account No. 500388.
- ☐ Enclosed is our Check No. _____ in the amount of \$ _____ to cover the additional claim fee and/or extension of time fees.
- ☒ Please charge the required fees, or any additional fees required to facilitate filing the enclosed response, to Deposit Account No. 500388 (Order No. CYTOP135).

Respectfully submitted,
BEYER WEAYER LLP


 Jeffrey K. Weaver
 Reg. No. 31,314

P.O. Box 70250
Oakland, CA 94612-0250

JAN 16 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mattheakis et al.

Attorney Docket No.: CYTOP135

Application No.: 10/623,486

Examiner: LILLING, HERBERT J

Filed: July 18, 2003

Group: 1651

Title: PREDICTING HEPATOTOXICITY USING
CELL BASED ASSAYS

CERTIFICATE OF FACSIMILE TRANSMISSION:

I hereby certify that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, Attn: Examiner Lilling, Fax No. (571) 273-8300, Alexandria, VA 22313-1450 on: January 16, 2007.

Signed: 

Mary Perry

AMENDMENT B

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BEST AVAILABLE COPY

Dear Sir:

In response to the Final Office Action dated October 3, 2006, please amend the above-identified patent application as follows:

Listing of Pending Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.